Drug Database
SI

sitagliptin phosphate + ipragliflozin L-proline (Sujanu / MK0431J)

✓ Approved

Kotobuki Pharmaceutical Co., Ltd. · DPP4 · Small Molecule

What is sitagliptin phosphate + ipragliflozin L-proline?

sitagliptin phosphate + ipragliflozin L-proline is a small molecule developed by Kotobuki Pharmaceutical Co., Ltd.. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesSujanu, MK0431J
CompanyKotobuki Pharmaceutical Co., Ltd.
Drug ClassSmall Molecule
Molecular TargetDPP4, SLC5A2
RouteOral (PO)
StatusApproved

Mechanism of Action

Molecular Targets

sitagliptin phosphate + ipragliflozin L-proline acts on 2 molecular targets:

DPP4dipeptidyl peptidase 4 (CD26, DPPIV)
SLC5A2solute carrier family 5 member 2 (SGLT2)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

sitagliptin phosphate + ipragliflozin L-proline is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Metabolism and nutrition disordersType 2 diabetes mellitus✓ Approved

Related Research Articles

PubMedCureus2026-09-20

Noncanonical Splice Site Disruption: +4 Intronic Variant in Phosphate-Regulating Endopeptidase Homolog, X-linked (PHEX Gene) Supported by In Silico Analysis in X-linked Hypophosphatemic Rickets.

Panqueba Arias Carlos F CF, Rojas Rodriguez Ingry K IK, Quero Rossi I RI, Baez Cielo C CC

X-linked hypophosphatemic rickets (XLH) is the most common inherited cause of renal phosphate wasting. It is typically caused by pathogenic variants in the phosphate-regulating endopeptidase homolog, X-linked (PHEX gene), which lead to increased levels of fibroblast growth factor 23 (FGF23). However, noncanonical intronic variants represent a significant diagnostic challenge, as they may not be detected by conventional genetic studies and require interpretation supported by bioinformatic tools. We present the case of a pediatric patient with postnatal short stature and progressive genu varum. Biochemical studies revealed hypophosphatemia with reduced tubular reabsorption of phosphate, while calcium, parathyroid hormone (PTH), and vitamin D levels were within normal ranges. Radiological findings were consistent with rickets. Initial clinical exome sequencing was negative. Subsequently, a targeted gene panel identified a previously unreported intronic variant in the PHEX gene (c.1768+4dup; chrX:22,219,105 T>TA). In silico analysis using SpliceAI demonstrated a high probability of donor splice site loss (DS_DL = 0.80), while Pangolin predicted a splice-disrupting effect (score = 0.72); collectively, these findings support a deleterious effect on mRNA splicing. This case highlights the importance of integrating clinical, biochemical, genetic, and computational data for the interpretation of noncanonical intronic variants, expanding the mutational spectrum described for PHEX in XLH.

PubMedOpen medicine (Warsaw, Poland)2026-09-20

Glucocorticoids combined with rituximab treatment for IgG4-related tubulointerstitial nephritis with diabetic nephropathy: a case report.

Wang Tianshu T, Zhang Jingjing J, Xu Yaguang Y

IgG4-related disease is a chronic immune-mediated disorder featuring elevated serum IgG4 levels and the tissue infiltration of IgG4-positive plasma cells. Kidney involvement in IgG4-related disease, known as IgG4-related kidney disease, most commonly manifests as tubulointerstitial nephritis. A 55-year-old male presented with acute kidney injury (creatinine=816 μmol/L), severe anemia, lymphadenopathy, and high IgG4 levels (13.89 g/L). Renal MRI and Chest CT showed diffuse renal abnormalities and mediastinal lymphadenopathy. Renal biopsy confirmed IgG4-related tubulointerstitial nephritis, complicated by IgA nephropathy and diabetic nephropathy. Initial glucocorticoid treatment was prescribed followed by 1.8 g rituximab consolidation therapy. Over 32 months follow-up, the patient's renal function significantly improved (creatinine 215 μmol/L) and his serum IgG4 levels normalized (0.89 g/L). This success of this case suggests that combination therapy may be a reasonable option in selected cases, and underscores the importance of an early diagnosis, pathological confirmation, and standardized immunosuppressive therapy for improving the outcomes in IgG4-related kidney disease.

PubMedOpen life sciences2026-09-20

Comparative analysis of vitamin C derivatives on ATP homeostasis across diverse cell types.

Goc Anna A, Sumera Waldemar W, Niedzwiecki Aleksandra A

Cellular energy homeostasis is tightly regulated by mitochondrial function and substrate availability. Vitamin C is a redox-active molecule with emerging roles in cellular metabolism; however, the metabolic impacts of structurally distinct vitamin C derivatives remain incompletely defined. In this study, we systematically compared l-ascorbic acid, dehydroascorbic acid, 6-O-palmitoyl-l-ascorbate, and mineral ascorbates (calcium, magnesium, sodium, and potassium salts) across multiple mammalian cell types. Cells were exposed to concentrations ranging from 60 to 500 µM, encompassing physiologically and pharmacologically relevant levels. The vitamin C derivatives induced cell type- and concentration-dependent modulation of intracellular ATP levels. Notably, HepG2 and renal epithelial cells exhibited robust ATP increases, whereas fibroblasts, myocytes, microglia, and skeletal muscle models displayed variable responses depending on the derivative and dose. Moreover, in skeletal muscle cells, co-treatment of standard l-ascorbic acid with select fatty acids did not yield additive bioenergetic effects, suggesting a localized, substrate-specific plateau or shared regulatory step in this specific cell model. Exposure to l-ascorbic acid induced selective increases in COX-1 without changes in SDH-A, consistent with rapid functional modulation of mitochondrial activity in myocytes and microglial cells only. Collectively, these findings demonstrate that vitamin C derivatives modulate cellular ATP levels within existing metabolic networks in a context-dependent manner, consistent with the modulation of mitochondrial-associated energy metabolism.

PubMedCureus2026-09-20

Valproate-Associated Hyperammonemic Encephalopathy Despite Nontoxic Serum Levels and Preserved Liver Function: A Case Report.

Ferreira Iara I, Pais Fátima F, Gonçalves Ermelinda E

Valproate-associated hyperammonemic encephalopathy (VHE) is a potentially serious adverse effect that may occur despite nontoxic serum valproate concentrations and preserved liver function. We report a 49-year-old man with intellectual disability and long-standing drug-resistant epilepsy treated with valproate, phenytoin, phenobarbital, cenobamate, levetiracetam, and several psychotropic medications. He was admitted with severe and persistent impairment of consciousness. Initial kidney and liver function were preserved, and brain computed tomography showed no acute abnormalities. Electroencephalography demonstrated diffuse and bilateral frontotemporal slowing without electrographic seizure activity. Serum ammonia was 88.1 µmol/L and subsequently increased to 126.5 µmol/L, while valproate concentrations remained therapeutic or subtherapeutic. Phenytoin was initially supratherapeutic, but correction of its concentration did not produce meaningful neurological improvement. An extended metabolic, nutritional, autoimmune, infectious, toxicologic, and hepatic evaluation revealed no alternative cause. VHE was suspected, and valproate was gradually withdrawn without levocarnitine. This was followed by sustained neurological recovery and a decrease in serum ammonia to 43.1 µmol/L. This case emphasizes the importance of measuring serum ammonia in patients receiving valproate who develop otherwise unexplained altered mental status, particularly in the setting of intellectual disability and extensive antiseizure polytherapy.

PubMedIranian journal of pharmaceutical research : IJPR2026-09-20

The Effectiveness of a Topical Turmeric-Based Formulation on Contact Dermatitis: A Randomized, Double-Blind, Controlled Trial.

Khatami Shabnam S, Sadati Lamardi Seyede Nargess SN, Najafi-Vosough Roya R, Mizani Azadeh A et al.

Contact dermatitis (CD) affects approximately 15% of adults worldwide, and commonly used treatments are often associated with adverse effects. Traditional medicine sources, including Persian medicine, offer promising alternatives. Based on the principles of Persian medicine, the formulation investigated in this study combines Curcuma longa L., Lawsonia inermis L., and Aristolochia rotunda L. (CLA) to achieve a synergistic therapeutic effect. This study aimed to evaluate the efficacy and safety of a 4-week intervention using CLA cream in patients with mild-to-moderate CD. A randomized, double-blind, placebo-controlled trial was conducted in 64 participants who were assigned to apply either CLA cream or the base cream. Assessments included demographic characteristics, the Dermatology Life Quality Index (DLQI), the Three-Item Severity Score (TIS), and skin parameters, including transepidermal water loss (TEWL), stratum corneum hydration, skin pH, and sebum production. Statistical analyses were performed using repeated-measures analysis of variance with least significant difference post hoc tests, Friedman tests, and Wilcoxon tests. The CLA group showed significantly greater decreases in TEWL and TIS scores than the control group (P = 0.004 and P = 0.003, respectively). In the within-group analysis, sebum production increased significantly after the intervention in the CLA group (P = 0.006). Stratum corneum hydration improved significantly in both groups. A 4-week course of CLA cream appears to ameliorate inflammatory symptoms in patients with mild-to-moderate contact dermatitis. Further large-scale, longer-duration trials are warranted to establish the clinical utility of CLA cream as a complementary therapeutic option.

PubMedISME communications2026-09-20

Black Sea picocyanobacteria exploit ancestral traits for energy and chlorophyll production in dark anoxia.

Bartosiewicz Maciej M, Cabello-Yeves Pedro J PJ, Eckert Ester M EM, Di Cesare Andrea A et al.

Picocyanobacteria, typically associated with oxygenated waters, also thrive in oxygen minimum zones (OMZs) and anoxic environments. The extent to which retention of diverse ancestral anaerobic traits facilitate their metabolic flexibility with regards to transitioning between oxic and anoxic habitats is poorly understood. Here, using Black Sea Cyanobium (BSA11S), we performed 13C-glucose and 15N-ammonium incubations coupled with nanoscale ion mass spectrometry (NanoSIMS) and transcriptomics to characterize the growth mode and gene expression during transition from light-to-dark and oxic-to-anoxic conditions. Incubated picocyanobacteria assimilate 13C-glucose and ammonium under anoxic-dark conditions, grow slowly without light, and retain the capability to synthesize photosynthetic pigments. These organisms moderately upregulate genes responsible for chlorophyll-a/bilin biosynthesis, uptake of C sources, debranching of glycogen storage, and the pentose phosphate pathway for ATP, NADH, and NADPH production, as well as genes involved in NAD+ regeneration, including proton-reduction hydrogen-metabolism coupled with lactic acid fermentation. Our results support the remarkable versatility, plasticity, and potential for mixotrophy in photoautotrophs that allow them to dominate diverse aquatic systems worldwide.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about sitagliptin phosphate + ipragliflozin L-proline